These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 23730210

  • 1. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
    Coppock JD, Wieking BG, Molinolo AA, Gutkind JS, Miskimins WK, Lee JH.
    Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
    [Abstract] [Full Text] [Related]

  • 2. mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.
    Coppock JD, Vermeer PD, Vermeer DW, Lee KM, Miskimins WK, Spanos WC, Lee JH.
    Oncotarget; 2016 Apr 26; 7(17):24228-41. PubMed ID: 27015118
    [Abstract] [Full Text] [Related]

  • 3. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
    Pogorzelski M, Ting S, Gauler TC, Breitenbuecher F, Vossebein I, Hoffarth S, Markowetz J, Lang S, Bergmann C, Brandau S, Jawad JA, Schmid KW, Schuler M, Kasper S.
    Cell Death Dis; 2014 Feb 27; 5(2):e1091. PubMed ID: 24577089
    [Abstract] [Full Text] [Related]

  • 4. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
    Shen YQ, Guerra-Librero A, Fernandez-Gil BI, Florido J, García-López S, Martinez-Ruiz L, Mendivil-Perez M, Soto-Mercado V, Acuña-Castroviejo D, Ortega-Arellano H, Carriel V, Diaz-Casado ME, Reiter RJ, Rusanova I, Nieto A, López LC, Escames G.
    J Pineal Res; 2018 Apr 27; 64(3):. PubMed ID: 29247557
    [Abstract] [Full Text] [Related]

  • 5. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
    Aderhold C, Faber A, Umbreit C, Birk R, Weiss C, Sommer JU, Hörmann K, Schultz JD.
    Anticancer Res; 2015 Apr 27; 35(4):1951-9. PubMed ID: 25862847
    [Abstract] [Full Text] [Related]

  • 6. mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model.
    Callejas-Valera JL, Iglesias-Bartolome R, Amornphimoltham P, Palacios-Garcia J, Martin D, Califano JA, Molinolo AA, Gutkind JS.
    Carcinogenesis; 2016 Oct 27; 37(10):1014-25. PubMed ID: 27538837
    [Abstract] [Full Text] [Related]

  • 7. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
    Herzog A, Bian Y, Vander Broek R, Hall B, Coupar J, Cheng H, Sowers AL, Cook JD, Mitchell JB, Chen Z, Kulkarni AB, Van Waes C.
    Clin Cancer Res; 2013 Jul 15; 19(14):3808-19. PubMed ID: 23640975
    [Abstract] [Full Text] [Related]

  • 8. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
    Sun ZJ, Zhang L, Hall B, Bian Y, Gutkind JS, Kulkarni AB.
    Clin Cancer Res; 2012 Oct 01; 18(19):5304-13. PubMed ID: 22859719
    [Abstract] [Full Text] [Related]

  • 9. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.
    Clin Cancer Res; 2015 Sep 01; 21(17):3946-56. PubMed ID: 25977343
    [Abstract] [Full Text] [Related]

  • 10. mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.
    Molinolo AA, Marsh C, El Dinali M, Gangane N, Jennison K, Hewitt S, Patel V, Seiwert TY, Gutkind JS.
    Clin Cancer Res; 2012 May 01; 18(9):2558-68. PubMed ID: 22409888
    [Abstract] [Full Text] [Related]

  • 11. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
    Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q, Gutkind JS.
    J Natl Cancer Inst; 2014 Sep 01; 106(9):. PubMed ID: 25099740
    [Abstract] [Full Text] [Related]

  • 12. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer.
    Spanos WC, Nowicki P, Lee DW, Hoover A, Hostager B, Gupta A, Anderson ME, Lee JH.
    Arch Otolaryngol Head Neck Surg; 2009 Nov 01; 135(11):1137-46. PubMed ID: 19917928
    [Abstract] [Full Text] [Related]

  • 13. Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients.
    Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR.
    Clin Cancer Res; 2017 Jun 15; 23(12):3072-3083. PubMed ID: 27986750
    [Abstract] [Full Text] [Related]

  • 14. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
    Okui T, Shimo T, Fukazawa T, Mohammad Monsur Hassan N, Honami T, Ibaragi S, Takaoka M, Naomoto Y, Sasaki A.
    Curr Cancer Drug Targets; 2013 Mar 15; 13(3):289-99. PubMed ID: 23016912
    [Abstract] [Full Text] [Related]

  • 15. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.
    Amornphimoltham P, Patel V, Leelahavanichkul K, Abraham RT, Gutkind JS.
    Cancer Res; 2008 Feb 15; 68(4):1144-53. PubMed ID: 18281490
    [Abstract] [Full Text] [Related]

  • 16. Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
    Li SH, Lin WC, Huang TL, Chen CH, Chiu TJ, Fang FM, Huang WT, Hsu CM, Luo SD, Lai CC, Su YY, Chuang HC, Chien CY.
    Head Neck; 2016 Apr 15; 38 Suppl 1():E844-52. PubMed ID: 25917382
    [Abstract] [Full Text] [Related]

  • 17. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line.
    Harris M, Wang XG, Jiang Z, Goldberg GL, Casadevall A, Dadachova E.
    Head Neck Oncol; 2011 Feb 12; 3(1):9. PubMed ID: 21314983
    [Abstract] [Full Text] [Related]

  • 18. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.
    Ekshyyan O, Rong Y, Rong X, Pattani KM, Abreo F, Caldito G, Chang JK, Ampil F, Glass J, Nathan CO.
    Mol Cancer Ther; 2009 Aug 12; 8(8):2255-65. PubMed ID: 19625495
    [Abstract] [Full Text] [Related]

  • 19. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
    Chou MH, Chuang HC, Lin YT, Tsai MH, Kao YH, Lin IC, Huang TL, Fang FM, Chien CY.
    Int J Mol Sci; 2021 Mar 17; 22(6):. PubMed ID: 33802643
    [Abstract] [Full Text] [Related]

  • 20. Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma.
    Hirashima K, Baba Y, Watanabe M, Karashima RI, Sato N, Imamura Y, Nagai Y, Hayashi N, Iyama KI, Baba H.
    Br J Cancer; 2012 Feb 28; 106(5):876-82. PubMed ID: 22333597
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.